Objectives: To describe a rapid workflow based on the direct detection of Escherichia coli (Ec) and Klebsiella pneumoniae (Kp) producing CTX-M extended-spectrum β-lactamase (ESBL) and/or carbapenemases (eg, KPC, VIM) from blood cultures (BCs) and the infectious disease (ID) consulting for timely appropriate antimicrobial therapy. Methods: This observational, retrospective study included adult patients with a first episode of Ec or Kp bloodstream infection (BSI) in a large Italian university hospital, where an inpatient ID consultation team (IDCT) has been operational. Results from the BCs tested for detecting bla CTX-M , bla KPC , bla NDM , bla OXA-48-like , and bla VIM genes by the eazyplex ® SuperBug CRE assay in Ec and Kp organisms had been notified for antimicrobial therapy consulting. Results: In 321 BSI episodes studied, we found that 151 (47.0%) of Ec or Kp organisms harbored bla CTX-M and/or bla KPC and/or bla VIM (meantime from BC collection: 18.5 h). Empirical antimicrobial treatment was appropriate in 21.8% (33/151) of BSIs, namely 5.9% (3/51) of BSIs caused by KPC/VIM producers and 30.0% (30/100) of BSIs caused by CTX-M producers. After notification of results, the IDCT modified antimicrobial therapy (mean time from BC collection: 20 h) such that the proportion of appropriate treatments increased to 84.8% (128/151) of BSIs, namely 70.6% (36/51) of BSIs caused by KPC/VIM producers and 92.0% (92/100) of BSIs caused by CTX-M producers. Conclusion: Our study shows that a rapid diagnostic-driven clinical strategy allowed for early prescription of potentially effective antimicrobial therapy in BSIs caused by CTX-M ESBL-and/or KPC/VIM carbapenemase-producing Ec and Kp organisms.
Background
Escherichia coli (Ec) and Klebsiella pneumoniae (Kp) are the leading causes of bloodstream infections (BSIs) involving gram-negative bacteria, and β-lactams are among the most used drugs for treatment of such infections. Globally, increasing attention is being focused on the growing involvement of extended-spectrum-β-lactamase (ESBL)-producing isolates of Ec and Kp in serious BSIs. 1, 2 This trend is due largely to the emergence of CTX-M ESBLs, a rapidly expanding group of enzymes that are being encountered with increasing frequency in both bacterial species. 3, 4 Carbapenems represent one therapeutic option for infections caused by multidrug-resistant (MDR) ESBL-producing organisms; however, resistance to this class of antibiotics has increased during the last decade. 5 Carbapenem-resistant Enterobacteriaceae, particularly Kp producing bla KPC , are now responsible for a new dramatic scenario and are emerging as a relevant cause of health care-associated BSIs in several countries, including Italy. [6] [7] [8] Detecting rapidly and accurately BSI pathogens is a critical factor for earlier implementation of effective treatment of these life-threatening infections. Although blood culture (BC) remains the gold standard for diagnosing BSIs, the time-consuming process of isolate identification/characterization with conventional culture-based methods has been improved by the development of faster technologies, allowing identification of the infecting pathogen directly from BC bottles. 9 In addition to matrix-assisted laser desorption ionization-time of flight mass spectrometry (eg, MALDI BioTyper TM system [Bruker Daltonics, Bremen, Germany]), various commercial BC-based nucleic acid assays can shorten the identification time of pathogens and/or resistance genes, 10 and have added value for antibiotic stewardship decisions by decreasing the time to initiating appropriate antibiotic therapy.
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To provide rapid pathogens' characterization for early appropriate treatment of patients with Ec-or Kp-BSI hospitalized in a CTX-M and KPC-endemic setting, we implemented the laboratory's BC workflow that uses the eazyplex ® SuperBug CRE assay (Amplex Diagnostics GmbH, Biolife italiana SRL, Milan, Italy) when Ec or Kp organisms were identified by direct MALDI BioTyper TM analysis from positive BCs. 10 Clinical experience to date shows that this panel identifies the CTX-M-1-group and CTX-M-9-group ESBLs and the VIM (−1 to −37), NDM (−1 to −7), KPC (−2 to −15), and OXA-48-like (−48, −162, −204, and −244) carbapenemases with high accuracy when applied directly to both cultured bacterial and urine samples. [16] [17] [18] 
Diagnostic and clinical definitions
Time to detection of growth (TTD) was the time from when the BC bottle entered into the BC system to when it signaled positive. The time to result (TTR) was the time elapsed between the BC system entry and completion of the aforementioned direct-detection procedure. We assessed the appropriateness of antibiotic treatments at the time of BC collection (empirical therapy) and after notification of the procedure (targeted therapy) or AST (definitive therapy) results. We defined the antimicrobial treatment as appropriate when the patient received the first (empirical) and/or subsequent (diagnostic-driven) antibiotic with known susceptibility by microbiology report.
Results
We studied 321 patients with Ec (n=214) or Kp (n=107) BSIs. respectively, with bla KPC-3 being the most commonly detected gene (Table 1) . Within few hours after BCs were drawn, physicians started empirical antimicrobial therapy in all the 321 patients. The antibiotics most frequently used were piperacillin-tazobactam (24.3%) and fluoroquinolones (23.7%) followed by carba (16.2%) and ESC (8.7%); when combination therapy was used, piperacillin-tazobactam plus amikacin (9.3%) was the most frequent antibiotic regimen. In most cases (85.0%), the physician in charge of the patient made the choice of the empirical treatment, and did not use a predefined protocol. As shown in Table 2 (Table 2 ), leading to a proportion of appropriate treatments up to 99.7% (320/321 patients) (Figure 2) . One patient never received effective therapy, as the infecting Kp isolate was resistant to all the antibiotics tested ( Table 1) .
Discussion
To the best of our knowledge, this study is the first large hospital-based report that has evaluated the effects of the rapid detection of Ec and Kp isolates producing bla CTX-M or patients with CTX-M-and carbaR-BSI, and none of these studies used the eazyplex ® SuperBug CRE assay as a rapid resistance detection method. Here, integrating this assay with MALDI BioTyper TM analysis, our diagnostic algorithm allowed the successful identification of all Ec and Kp producing bla CTX-M , and/or bla KPC and/or bla VIM , and, more importantly, the antimicrobial streamlining in the course of BSI. Therefore, this study has some strengths. First, the results by the proposed laboratory workflow are obtainable in a mean time of 18 h, which may help clinicians to provide more therapy that is effective during the early period of clinical illness and may facilitate rapid decisions regarding isolating patients to prevent transmission. Second, the procedure underlying this workflow is simple and easy to perform and requires minimal training. Third, rapidly detecting a specific type of carbapenemase is particularly important because of the introduction of new antibiotics potentially active against certain carbapenemases into the clinical practice. In this context, our workflow is undoubtedly a positive contribution to infection control/effective treatment of patients.
Prior to the implementation of the rapid BC strategy in our hospital, we noted significant delays in initiating effective antimicrobial therapy. 2, 25 Conversely, based on the strategy shown here, the IDCT specialists switched 64.7% of patients with KPC/VIM BSI and 62.0% of patients with CTX-M BSI from inappropriate empirical antimicrobial regimen to effective coverage within a mean time of 20 h. In the remaining 23 patients on inappropriate empirical therapy, 15 of whom were infected by KPC producers and eight by CTX-M producers, the original regimen was discontinued, but each patient was treated with a drug against which his/her isolate had displayed resistance in AST testing. All 15 patients with KPC BSI that maintained an ineffective coverage received a colistin-based regimen. A problem of considerable importance is the increasing rate of colistin-resistance among KPC-producing Kp isolates because of its shortage of therapeutic options in patients with BSIs. 26 There is an endemic widespread of such isolates in Italian healthcare facilities, 27, 28 and it was approximately 40% in our hospital. The ineffective drug was piperacillin-tazobactam in all but one patients infected by CTX-M producers. Carbapenems seem to be a suitable option for treating severe infections due to those organisms; however, their increased use exerts selection pressure for carbapenem resistance. Therefore, experts have suggested carbapenem-sparing antibiotic regimens, particularly in settings such as ours where carbapenemresistant isolates are common. Although there is emerging evidence that piperacillin-tazobactam may be a good choice for treating ESBL BSIs, its role is still controversial, particularly for BSIs from non-urinary sources. [29] [30] [31] [32] [33] Additionally, the susceptibility of ESBL producers to piperacillin-tazobactam is less predictable than their susceptibility to carbapenems. Among our isolates, rates of resistance ranged from 31.2% of CTX-M-producing Ec isolates to 73.9% of CTX-M-producing Kp isolates. Therefore, physicians need to base their decisions regarding the empirical use of this antibiotic, until susceptibility results are available, on a sound knowledge of the local susceptibility patterns and the patient's clinical condition. This study has some well-acknowledged limitations. First, as we conducted our analysis in a single center, the results are not necessarily applicable to other hospitals, particularly those with very low rates of Enterobacteriaceae infections caused by CTX-M and/ or carbapenemase producers. Second, the eazyplex ® SuperBug CRE assay's main weakness is its inability to identify ESBLs other than CTX-M, plasmidic AmpC, and some OXA-48-like enzymes, which are found among currently spreading MDR members of Enterobacteriaceae. 4, 28 Therefore, without the ability to detect these resistance determinants, the assay would miss a significant proportion of resistant isolates if implemented in settings where isolates harboring those genes occur.
Conclusion
Our combined use of the MALDI BioTyper TM analysis and eazyplex ® SuperBug CRE assay can be a reliable, timesaving alternative to the conventional laboratory diagnosis of BSIs caused by Ec or Kp organisms with MDR determinants (ie, CTX-M ESBLs and carbapenemases). Importantly, this rapid diagnosis can enable physicians to begin appropriate antimicrobial therapy precociously. However, the applicability of our diagnostic workflow does depend on the conditions dictated by aforementioned limitations, as well as further larger studies are necessary to validate and confirm the present findings.
